Endocrinol Metab.  2019 Jun;34(2):169-178. 10.3803/EnM.2019.34.2.169.

Does Radiofrequency Ablation Induce Neoplastic Changes in Benign Thyroid Nodules: A Preliminary Study

• Ha SM
• Shin JY
• Baek JH
• Song DE
• Chung SR
• Choi YJ
• Lee JH

• KMID: 2450517
• DOI: http://doi.org/10.3803/EnM.2019.34.2.169

Abstract

BACKGROUND
To evaluate the clinical feasibility of radiofrequency ablation (RFA) of benign thyroid nodules along with cytomorphological alteration, and any malignant transformation through biopsy.
METHODS
The data were retrospectively collected between April 2008 and June 2013 and core needle biopsy (CNB) was performed on 16 benign thyroid nodules previously treated using RFA. The parameters of the patients were compared, between the time of enrollment and the last follow-up examination, using linear mixed model statistical analysis.
RESULTS
No atypical cells or neoplastic transformation were detected in the undertreated peripheral portion of treated benign nodules on the CNB specimen. RFA altered neither the thyroid capsule nor the thyroid tissue adjacent to the treated area. On histopathological examinations, we observed 81.2% acellular hyalinization, which was the most common finding. After a mean follow-up period of over 5 years, the mean volume of thyroid nodule had decreased to 6.4±4.2 mL, with a reduction rate of 81.3%±5.8% (P<0.0001).
CONCLUSION
RFA is a technically feasible treatment method for benign thyroid nodules, with no carcinogenic effect or tissue damage of the normal thyroid tissue adjacent to the RFA-treated zone.

Keyword

Thyroid nodule; Radiofrequency ablation; Ultrasonography; Pathology; Biopsy, large-core needle

MeSH Terms

Biopsy
Biopsy, Large-Core Needle
Catheter Ablation*
Follow-Up Studies
Humans
Hyalin
Methods
Pathology
Retrospective Studies
Thyroid Gland*
Thyroid Nodule*
Ultrasonography

Figure

• 

  Fig. 1 Orientation of the thyroid core needle biopsy. (A) Normal thyroid tissue is noted on the left lower corner (blue arrow). (B) Less than half near the normal thyroid tissue is defined as ‘peripheral’ (red arrow, A). (C) More than half distance from the normal thyroid tissue is defined as ‘central’ (black arrow, A) with focal remaining benign follicular lesion on the central side (H&E stain, ×100).

• 

  Fig. 2 Treatment effect after radiofrequency ablation (RFA) of a benign follicular nodule. (A) Note acellular dense hyalinization (black arrow) and the remaining benign follicular lesion (red arrow) (×40). (B) The remaining benign follicular lesion shows mixed benign thyroid follicles with variable sizes and nuclear enlargement without nuclear atypia at higher magnification (H&E stain, ×200).

• 

  Fig. 3 Coexistence of the slightly viable area and totally infarcted area after radiofrequency ablation (RFA). (A) Slightly viable area (black arrow) and totally infarcted area after RFA (red arrow) (H&E stain, ×100). (B) Immunohistochemical (IHC) staining for the human mitochondria antibody. Both viable and totally infarcted areas are negative for human mitochondria antibody (×100). IHC stains for (C) thyroglobulin and (D) thyroid transcription factor-1 (TTF-1). The totally infarcted area shows loss of expression for thyroglobulin and TTF-1, whereas the slightly viable area is positive for both (×100).

Reference

1. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977; 7:481–493. PMID: 598014.

2. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968; 69:537–540. PMID: 5673172.

3. Gharib H, Hegedus L, Pacella CM, Baek JH, Papini E. Clinical review: nonsurgical, image-guided, minimally invasive therapy for thyroid nodules. J Clin Endocrinol Metab. 2013; 98:3949–3957. PMID: 23956350.

4. Bernardi S, Dobrinja C, Fabris B, Bazzocchi G, Sabato N, Ulcigrai V, et al. Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules. Int J Endocrinol. 2014; 2014:934595. PMID: 25045352.

5. Faggiano A, Ramundo V, Assanti AP, Fonderico F, Macchia PE, Misso C, et al. Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study. J Clin Endocrinol Metab. 2012; 97:4439–4445. PMID: 23019349.

6. Hamidi O, Callstrom MR, Lee RA, Dean D, Castro MR, Morris JC, et al. Outcomes of radiofrequency ablation therapy for large benign thyroid nodules: a mayo clinic case series. Mayo Clin Proc. 2018; 93:1018–1025. PMID: 29572016.

7. Kim JH, Baek JH, Sung JY, Min HS, Kim KW, Hah JH, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery. Int J Hyperthermia. 2017; 33:212–219. PMID: 27590679.

8. Bennedbaek FN, Karstrup S, Hegedus L. Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur J Endocrinol. 1997; 136:240–250. PMID: 9100545.

9. Crescenzi A, Papini E, Pacella CM, Rinaldi R, Panunzi C, Petrucci L, et al. Morphological changes in a hyperfunctioning thyroid adenoma after percutaneous ethanol injection: histological, enzymatic and sub-microscopical alterations. J Endocrinol Invest. 1996; 19:371–376. PMID: 8844457.

10. Monzani F, Caraccio N, Basolo F, Iacconi P, LiVolsi V, Miccoli P. Surgical and pathological changes after percutaneous ethanol injection therapy of thyroid nodules. Thyroid. 2000; 10:1087–1092. PMID: 11201854.

11. Piana S, Riganti F, Froio E, Andrioli M, Pacella CM, Valcavi R. Pathological findings of thyroid nodules after percutaneous laser ablation: a series of 22 cases with cyto-histological correlation. Endocr Pathol. 2012; 23:94–100. PMID: 22246921.

12. Valcavi R, Piana S, Bortolan GS, Lai R, Barbieri V, Negro R. Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma: a feasibility study on three cases with pathological and immunohistochemical evaluation. Thyroid. 2013; 23:1578–1582. PMID: 23978269.

13. Dobrinja C, Bernardi S, Fabris B, Eramo R, Makovac P, Bazzocchi G, et al. Surgical and pathological changes after radiofrequency ablation of thyroid nodules. Int J Endocrinol. 2015; 2015:576576. PMID: 26265914.

14. Kuma K, Matsuzuka F, Kobayashi A, Hirai K, Morita S, Miyauchi A, et al. Outcome of long standing solitary thyroid nodules. World J Surg. 1992; 16:583–587. PMID: 1413828.

15. Lim HK, Lee JH, Ha EJ, Sung JY, Kim JK, Baek JH. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. Eur Radiol. 2013; 23:1044–1049. PMID: 23096937.

16. Austin PC, Lee DS, D'Agostino RB, Fine JP. Developing points-based risk-scoring systems in the presence of competing risks. Stat Med. 2016; 35:4056–4072. PMID: 27197622.

17. Yeon JS, Baek JH, Lim HK, Ha EJ, Kim JK, Song DE, et al. Thyroid nodules with initially nondiagnostic cytologic results: the role of core-needle biopsy. Radiology. 2013; 268:274–280. PMID: 23525204.

18. Na DG, Baek JH, Jung SL, Kim JH, Sung JY, Kim KS, et al. Core needle biopsy of the thyroid: 2016 consensus statement and recommendations from Korean Society of Thyroid Radiology. Korean J Radiol. 2017; 18:217–237. PMID: 28096731.

19. Jung CK, Baek JH. Recent advances in core needle biopsy for thyroid nodules. Endocrinol Metab (Seoul). 2017; 32:407–412. PMID: 29271614.

20. Trimboli P, Giovanella L. The significance of having an excellent patient's comfort with thyroid core needle biopsy. Endocrinol Metab (Seoul). 2018; 33:53–54. PMID: 29589388.

21. Cibas ES, Ali SZ. NCI Thyroid FNA State of the Science Conference. The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol. 2009; 132:658–665. PMID: 19846805.

22. Jung CK, Min HS, Park HJ, Song DE, Kim JH, Park SY, et al. Pathology reporting of thyroid core needle biopsy: a proposal of the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group. J Pathol Transl Med. 2015; 49:288–299. PMID: 26081825.

23. Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol. 2008; 18:1244–1250. PMID: 18286289.

24. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol. 2012; 13:117–125. PMID: 22438678.

25. Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C, Assanti AP, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid. 2009; 19:219–225. PMID: 19265492.

26. Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH. Radiofrequency ablation (RFA) of benign thyroid nodules in patients with incompletely resolved clinical problems after ethanol ablation (EA). World J Surg. 2010; 34:1488–1493. PMID: 20376445.

27. Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid. 2006; 16:361–367. PMID: 16646682.

28. Na DG, Kim JH, Sung JY, Baek JH, Jung KC, Lee H, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid. 2012; 22:468–475. PMID: 22304417.

29. Cochand-Priollet B, Dahan H, Laloi-Michelin M, Polivka M, Saada M, Herman P, et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid. 2011; 21:1067–1073. PMID: 21875347.

30. Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol. 2011; 165:447–453. PMID: 21724837.

31. Dunderovic D, Lipkovski JM, Boricic I, Soldatovic I, Bozic V, Cvejic D, et al. Defining the value of CD56, CK19, galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol. 2015; 10:196. PMID: 26503236.

32. Ke S, Ding XM, Kong J, Gao J, Wang SH, Cheng Y, et al. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med. 2010; 8:73. PMID: 20667141.

33. Kong J, Kong J, Pan B, Ke S, Dong S, Li X, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA. PLoS One. 2012; 7:e37266. PMID: 22615958.

34. Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med. 2003; 138:315–318. PMID: 12585829.

35. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005; 237:794–800. PMID: 16304103.

36. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16:109–142. PMID: 16420177.

37. Park HS, Baek JH, Choi YJ, Lee JH. Innovative techniques for image-guided ablation of benign thyroid nodules: combined ethanol and radiofrequency ablation. Korean J Radiol. 2017; 18:461–469. PMID: 28458598.

38. Sim JS, Baek JH, Lee J, Cho W, Jung SI. Radiofrequency ablation of benign thyroid nodules: depicting early sign of regrowth by calculating vital volume. Int J Hyperthermia. 2017; 33:905–910. PMID: 28540795.